Emcure cuts semaglutide injection price by average 47%

Mumbai: Emcure Pharmaceuticals has reduced the price of its weight management drug Poviztra (semaglutide injection) across India by an average of 47% across dosages in a bid to widen patient access.

The starting dose price is cut by 55% to Rs 3,999 per month (four weekly doses). The innovator semaglutide is available in a once-weekly pen device in five strengths of 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg and a maintenance dose of 2.4 mg with the highest dose priced at Rs 8,999 for a month’s supply.

Emcure has a marketing tie-up with the Danish innovator Novo Nordisk to distribute and commercialise another brand of semaglutide under the name Poviztra.


The price revision is effective April 3.

“The revised pricing of Poviztra is a step towards making scientifically validated weight-management therapies more accessible and affordable to a wider patient base,” said Satish Mehta, Chief Executive Officer and Managing Director, Emcure Pharma.

“India is grappling with a growing obesity epidemic, with nearly 254 million people living with generalised obesity and 351 million living with abdominal obesity. Improving access to a globally established molecule like semaglutide is crucial to addressing this public health challenge at scale,” he added.